help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shih, I.-M.
Right arrow Articles by Kurman, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, I.-M.
Right arrow Articles by Kurman, R. J.
(American Journal of Pathology. 2004;164:1511-1518.)
© 2004 American Society for Investigative Pathology

Review

Ovarian Tumorigenesis

A Proposed Model Based on Morphological and Molecular Genetic Analysis

Ie-Ming Shih and Robert J. Kurman

From the Departments of Pathology, Oncology and Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Abstract

The pathogenesis of ovarian carcinoma, the most lethal gynecological malignancy, is unknown because of the lack of a tumor progression model. Based on a review of recent clinicopathological and molecular studies, we propose a model for their development. In this model, surface epithelial tumors are divided into two broad categories designated type I and type II tumors that correspond to two main pathways of tumorigenesis. Type I tumors tend to be low-grade neoplasms that arise in a stepwise manner from borderline tumors whereas type II tumors are high-grade neoplasms for which morphologically recognizable precursor lesions have not been identified, so-called de novo development. As serous tumors are the most common surface epithelial tumors, low-grade serous carcinoma is the prototypic type I tumor and high-grade serous carcinoma is the prototypic type II tumor. In addition to low-grade serous carcinomas, type I tumors are composed of mucinous carcinomas, endometrioid carcinomas, malignant Brenner tumors, and clear cell carcinomas. Type I tumors are associated with distinct molecular changes that are rarely found in type II tumors, such as BRAF and KRAS mutations for serous tumors, KRAS mutations for mucinous tumors, and ß-catenin and PTEN mutations and microsatellite instability for endometrioid tumors. Type II tumors include high-grade serous carcinoma, malignant mixed mesodermal tumors (carcinosarcoma), and undifferentiated carcinoma. There are very limited data on the molecular alterations associated with type II tumors except frequent p53 mutations in high-grade serous carcinomas andmalignant mixed mesodermal tumors (carcinosarcomas). This model of carcinogenesis reconciles the relationship of borderline tumors to invasive carcinoma and provides a morphological and molecular framework for studies aimed at elucidating the pathogenesis of ovarian cancer.




This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
V. R. Iyer and S. I. Lee
MRI, CT, and PET/CT for Ovarian Cancer Detection and Adnexal Lesion Characterization
Am. J. Roentgenol., February 1, 2010; 194(2): 311 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
N. Lalwani, A. K. P. Shanbhogue, R. Vikram, A. Nagar, J. Jagirdar, and S. R. Prasad
Current Update on Borderline Ovarian Neoplasms
Am. J. Roentgenol., February 1, 2010; 194(2): 330 - 336.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. A. Rossing, K. G. Wicklund, K. L. Cushing-Haugen, and N. S. Weiss
Predictive Value of Symptoms for Early Detection of Ovarian Cancer
J Natl Cancer Inst, January 28, 2010; (2010): djp500v1 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. A. Edson, A. K. Nagaraja, and M. M. Matzuk
The Mammalian Ovary from Genesis to Revelation
Endocr. Rev., October 1, 2009; 30(6): 624 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang
Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas
Cancer Res., May 1, 2009; 69(9): 4036 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. R. Cochrane, N. S. Spoelstra, E. N. Howe, S. K. Nordeen, and J. K. Richer
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
Mol. Cancer Ther., May 1, 2009; 8(5): 1055 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al.
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Am. J. Pathol., May 1, 2009; 174(5): 1597 - 1601.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Sasaki, M. Narisawa-Saito, T. Yugawa, M. Fujita, H. Tashiro, H. Katabuchi, and T. Kiyono
Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes
Carcinogenesis, March 1, 2009; 30(3): 423 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. M Olsen, A. C Green, C. M Nagle, S. J Jordan, D. C Whiteman, C. J Bain, P. M Webb, and on behalf of the Australian Cancer Study Group (Ov
Epithelial ovarian cancer: testing the 'androgens hypothesis'
Endocr. Relat. Cancer, December 1, 2008; 15(4): 1061 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Levanon, C. Crum, and R. Drapkin
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
J. Clin. Oncol., November 10, 2008; 26(32): 5284 - 5293.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. S. Anglesio, J. M. Arnold, J. George, A. V. Tinker, R. Tothill, N. Waddell, L. Simms, B. Locandro, S. Fereday, N. Traficante, et al.
Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors
Mol. Cancer Res., November 1, 2008; 6(11): 1678 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Engels, S. K. Knauer, S. Loibl, V. Fetz, P. Harter, A. Schweitzer, A. Fisseler-Eckhoff, F. Kommoss, L. Hanker, V. Nekljudova, et al.
NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas
Cancer Res., July 1, 2008; 68(13): 5159 - 5166.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. J. Nam, H. Yoon, S. W. Kim, H. Kim, Y. T. Kim, J. H. Kim, J. W. Kim, and S. Kim
MicroRNA Expression Profiles in Serous Ovarian Carcinoma
Clin. Cancer Res., May 1, 2008; 14(9): 2690 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. N. Landen Jr, M. J. Birrer, and A. K. Sood
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Zecchini, M. Bianchi, N. Colombo, R. Fasani, G. Goisis, C. Casadio, G. Viale, J. Liu, M. Herlyn, A. K. Godwin, et al.
The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium
Cancer Res., February 15, 2008; 68(4): 1110 - 1118.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
W G McCluggage
My approach to and thoughts on the typing of ovarian carcinomas
J. Clin. Pathol., February 1, 2008; 61(2): 152 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
H. A. Adissu, E. K. Asem, and S. A. Lelievre
Three-Dimensional Cell Culture to Model Epithelia in the Female Reproductive System
Reproductive Sciences, December 1, 2007; 14(8_suppl): 11 - 19.
[Abstract] [PDF]

Home page
 Mol Cancer ResHome page
K. D. Cowden Dahl, R. Zeineldin, and L. G. Hudson
PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor-Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells
Mol. Cancer Res., May 1, 2007; 5(5): 413 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Itamochi, J. Kigawa, Y. Kanamori, T. Oishi, C. Bartholomeusz, R. Nahta, F. J. Esteva, N. Sneige, N. Terakawa, and N. T. Ueno
Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
Mol. Cancer Ther., January 1, 2007; 6(1): 227 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Denkert, J. Budczies, T. Kind, W. Weichert, P. Tablack, J. Sehouli, S. Niesporek, D. Konsgen, M. Dietel, and O. Fiehn
Mass Spectrometry-Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors.
Cancer Res., November 15, 2006; 66(22): 10795 - 10804.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K A Voutilainen, M A Anttila, S M Sillanpaa, K M Ropponen, S V Saarikoski, M T Juhola, and V-M Kosma
Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer
J. Clin. Pathol., May 1, 2006; 59(5): 460 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Erkanli, D. D. Taylor, D. Dean, F. Eksir, D. Egger, J. Geyer, B. H. Nelson, B. Stone, H. A. Fritsche, and R. B.S. Roden
Application of Bayesian Modeling of Autologous Antibody Responses against Ovarian Tumor-Associated Antigens to Cancer Detection
Cancer Res., February 1, 2006; 66(3): 1792 - 1798.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. W. Wamunyokoli, T. Bonome, J.-Y. Lee, C. M. Feltmate, W. R. Welch, M. Radonovich, C. Pise-Masison, J. Brady, K. Hao, R. S. Berkowitz, et al.
Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance
Clin. Cancer Res., February 1, 2006; 12(3): 690 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Yen, C.-Y. Hsu, T.-L. Mao, T-C. Wu, R. Roden, T.-L. Wang, and I.-M. Shih
Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma
Clin. Cancer Res., February 1, 2006; 12(3): 827 - 831.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Bonome, J.-Y. Lee, D.-C. Park, M. Radonovich, C. Pise-Masison, J. Brady, G. J. Gardner, K. Hao, W. H. Wong, J. C. Barrett, et al.
Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary
Cancer Res., November 15, 2005; 65(22): 10602 - 10612.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I.-M. Shih and R. J. Kurman
Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Shedden, M. P. Kshirsagar, D. R. Schwartz, R. Wu, H. Yu, D. E. Misek, S. Hanash, H. Katabuchi, L. H. Ellenson, E. R. Fearon, et al.
Histologic Type, Organ of Origin, and Wnt Pathway Status: Effect on Gene Expression in Ovarian and Uterine Carcinomas
Clin. Cancer Res., March 15, 2005; 11(6): 2123 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Isayeva, C. Ren, and S. Ponnazhagan
Recombinant Adeno-Associated Virus 2-Mediated Antiangiogenic Prevention in a Mouse Model of Intraperitoneal Ovarian Cancer
Clin. Cancer Res., February 1, 2005; 11(3): 1342 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-C. Chen, G. Pohl, T.-L. Wang, P. J. Morin, B. Risberg, G. B. Kristensen, A. Yu, B. Davidson, and I.-M. Shih
Apolipoprotein E Is Required for Cell Proliferation and Survival in Ovarian Cancer
Cancer Res., January 1, 2005; 65(1): 331 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-L. Ho, R. J. Kurman, R. Dehari, T.-L. Wang, and I.-M. Shih
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Cancer Res., October 1, 2004; 64(19): 6915 - 6918.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-Y. Hsu, R. Bristow, M. S. Cha, B. G. Wang, C.-L. Ho, R. J. Kurman, T.-L. Wang, and I.-M. Shih
Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Clin. Cancer Res., October 1, 2004; 10(19): 6432 - 6436.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society for Investigative Pathology.